Lynagh Robert, Ishak Mark, Georges Joseph, Lopez Danielle, Osman Hany, Kakareka Michael, Boyer Brandon, Goldman H Warren, Eschbacher Jennifer, Preul Mark C, Nakaji Peter, Turtz Alan, Yocom Steven, Appelt Denah
1Department of Neurosurgery, Philadelphia College of Osteopathic Medicine, Philadelphia, Pennsylvania.
2Massachusetts General Hospital, Wellman Center for Photomedicine, Boston, Massachusetts.
J Neurosurg. 2019 Feb 22:1-7. doi: 10.3171/2018.11.JNS18629.
OBJECTIVEAccurate histopathological diagnoses are often necessary for treating neuro-oncology patients. However, stereotactic biopsy (STB), a common method for obtaining suspicious tissue from deep or eloquent brain regions, fails to yield diagnostic tissue in some cases. Failure to obtain diagnostic tissue can delay initiation of treatment and may result in further invasive procedures for patients. In this study, the authors sought to determine if the coupling of in vivo optical imaging with an STB system is an effective method for identification of diagnostic tissue at the time of biopsy.METHODSA minimally invasive fiber optic imaging system was developed by coupling a 0.65-mm-diameter coherent fiber optic fluorescence microendoscope to an STB system. Human U251 glioma cells were transduced for stable expression of blue fluorescent protein (BFP) to produce U251-BFP cells that were utilized for in vitro and in vivo experiments. In vitro, blue fluorescence was confirmed, and tumor cell delineation by fluorescein sodium (FNa) was quantified with fluorescence microscopy. In vivo, transgenic athymic rats implanted with U251-BFP cells (n = 4) were utilized for experiments. Five weeks postimplantation, the rats received 5-10 mg/kg intravenous FNa and underwent craniotomies overlying the tumor implantation site and contralateral normal brain. A clinical STB needle containing our 0.65-mm imaging fiber was passed through each craniotomy and images were collected. Fluorescence images from regions of interest ipsilateral and contralateral to tumor implantation were obtained and quantified.RESULTSLive-cell fluorescence imaging confirmed blue fluorescence from transduced tumor cells and revealed a strong correlation between tumor cells quantified by blue fluorescence and FNa contrast (R2 = 0.91, p < 0.001). Normalized to background, in vivo FNa-mediated fluorescence intensity was significantly greater from tumor regions, verified by blue fluorescence, compared to contralateral brain in all animals (301.7 ± 34.18 relative fluorescence units, p < 0.001). Fluorescence intensity measured from the tumor margin was not significantly greater than that from normal brain (p = 0.89). Biopsies obtained from regions of strong fluorescein contrast were histologically consistent with tumor.CONCLUSIONSThe authors found that in vivo fluorescence imaging with an STB needle containing a submillimeter-diameter fiber optic fluorescence microendoscope provided direct visualization of neoplastic tissue in an animal brain tumor model prior to biopsy. These results were confirmed in vivo with positive control cells and by post hoc histological assessment. In vivo fluorescence guidance may improve the diagnostic yield of stereotactic biopsies.
目的
准确的组织病理学诊断对于神经肿瘤患者的治疗通常是必要的。然而,立体定向活检(STB)作为从深部或功能区脑区获取可疑组织的常用方法,在某些情况下无法获取诊断性组织。无法获取诊断性组织会延迟治疗的开始,并可能导致患者接受进一步的侵入性手术。在本研究中,作者试图确定体内光学成像与STB系统的结合是否是活检时识别诊断性组织的有效方法。
方法
通过将直径0.65毫米的相干光纤荧光显微内窥镜与STB系统耦合,开发了一种微创光纤成像系统。对人U251胶质瘤细胞进行转导,使其稳定表达蓝色荧光蛋白(BFP),以产生用于体外和体内实验的U251 - BFP细胞。在体外,确认了蓝色荧光,并用荧光显微镜对荧光素钠(FNa)勾勒肿瘤细胞的情况进行了定量分析。在体内,将植入U251 - BFP细胞的转基因无胸腺大鼠(n = 4)用于实验。植入后5周,大鼠静脉注射5 - 10 mg/kg FNa,并在肿瘤植入部位及对侧正常脑上方进行开颅手术。将含有我们0.65毫米成像光纤的临床STB针穿过每个开颅部位并采集图像。获取并量化肿瘤植入同侧和对侧感兴趣区域的荧光图像。
结果
活细胞荧光成像证实了转导肿瘤细胞发出的蓝色荧光,并揭示了通过蓝色荧光定量的肿瘤细胞与FNa对比度之间的强相关性(R2 = 0.91,p < 0.001)。与背景相比,在所有动物中,经蓝色荧光证实肿瘤区域的体内FNa介导的荧光强度明显高于对侧脑(301.7 ± 34.18相对荧光单位,p < 0.001)。从肿瘤边缘测得的荧光强度并不显著高于正常脑(p = 0.89)。从强荧光素对比度区域获取的活检组织在组织学上与肿瘤一致。
结论
作者发现,使用含有亚毫米直径光纤荧光显微内窥镜的STB针进行体内荧光成像,在活检前可直接观察动物脑肿瘤模型中的肿瘤组织。这些结果在体内通过阳性对照细胞和事后组织学评估得到了证实。体内荧光引导可能会提高立体定向活检的诊断率。